Completed PHASE4 INTERVENTIONAL 2-arm NCT00992394

Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept (ReSPONSE)

Randomized Open-label Study Comparing 2 Different Strategies For Management Of Subjects With Plaque Psoriasis Who Have Responded To Etanercept Treatment

Sponsor: Pfizer

Conditions Psoriasis

Interventions etanercept

Updated 8 times since 2017 Last updated: Dec 4, 2015 Started: Jan 31, 2010 Primary completion: Apr 30, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Psoriasis and is currently completed. Pfizer leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abu Dhabi, United Arab Emirates , Alcorcón, Spain , Alicante, Spain , Ankara, Turkey (Türkiye) , Athens, Greece , Berlin, Germany , Besançon, France , Bochum, Germany , Bornova / Izmir, Turkey (Türkiye) , Budapest, Hungary and 30 more locations